Journal of International Oncology››2013,Vol. 40››Issue (2): 117-119.

Previous ArticlesNext Articles

Changes of estrogen receptor, progesterone receptor and C-erbB-2 expressions in different scheme pre- and post-neoadjuvant chemotherapies for breast cancer

SHI Peng-Liang, ZHANG Nai-Qian, ZHANG Guo-Qiang

  1. Department of Breast Surgery-Ward 1, Third Affiliated Hospital of Harbin Medical University, Harbin 150001 , China
  • Online:2013-02-08Published:2013-01-25
  • Contact:Corresponding author: ZHANG Guo-qiang, E-mail: 6-fu@163.com E-mail:6-fu@163.com

Abstract:Neoadjuvant chemotherapy is widely used in the therapy of locally advanced breast cancer. In the recent studies, the expressions of ER, PR and C-erbB-2 in tumor may change in different scheme pre- and post-neoadjuvant chemotherapies for breast cancer. It is obviously changed in the neoadjuvant chemotherapy scheme of anthracyclines and paclitaxel/docetaxel, but hardly changed in anthracycline-based neoadjuvant chemotherapy scheme.

Key words:Breast neoplasms,Neoadjuvant chemotherapy,Receptors, estrogen,Receptors, progesterone,Receptors, erbB-2